questionText: To ask the Secretary of State for Health and Social Care, whether NICE plans to amend its guidance on the treatment of locally advanced high-risk non-metastatic prostate cancer to recommend the use of abiraterone acetate in England.
answerText: Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by the National Institute for Health and Care Excellence (NICE) for such use. NHS England is currently considering a clinical policy propo...
heading: Prostate Cancer: Drugs